ZFC - Carbonyl Iron + Folic Acid + Zinc Sulfate | VetSafeCare.Com

Brand

ZFC

Carbonyl Iron + Folic Acid + Zinc Sulfate — Silco Pharmaceutical Ltd.
(50mg + 0.5mg + 61.8mg) / capsule (timed release)

Alternatives

30

Routes

PO

Presentations

1

Generic profile Browse alternatives View combinations

Presentations

Capsule (Timed Release) · (50mg + 0.5mg + 61.8mg) / capsule (timed release)

1 capsule (timed release)

৳3

Dose rules

No structured dose rules are linked to this brand yet.

Dose reference

Human

Adult: One Capsule daily before food or as directed by the physician.

Clinical notes

Applications:

N/A

Indication Notes:
It is indicated for the treatment and prophylaxis of Iron, Folic Acid and Zinc deficiency especially during pregnancy and lactation.
Avoid In:

N/A

Contraindication Notes:
It is contraindicated in patients with known hypersensitivity to any of its component or those with Iron overload.
This timed-release capsule is the combined preparation of Carbonyl Iron, Folic Acid and Zinc Sulphate Monohydrate. It contains Carbonyl Iron with not less than 98% Iron content. Carbinyl Iron, having high bioavailability and low toxicity is safer and more effective choice for iron supplementation.
Carbonyl Iron decreases the absorption of tetracycline antibiotics, quinolone antibiotics, levodopa, levothyroxine, methyldopa and penecillamine. Folic Acid interacts with antiepileptics, so plasma concentrations of phenobarbital, phenytoin and primidone are possibly reduced.
Gastrointestinal irritations such as nausea, anorexia, vomiting, discomfort, constipation and diarrhoea may occur. Patients may complain of dark stool. Carbonyl Iron pellets incorporated into the capsules to reduce the possibility of gastrointestinal irritations. Rarely there may be allergic reactions.
Symptoms of Carbonyl Iron include decreased energy, nausea, abdominal pain, tarry stool, weak, rapid pulse, fever, coma, seizures.
Use of any drug during first trimester of pregnancy should be avoided if possible. Thus administration of Iron during the first trimester requires definite evidence of Iron deficiency. Prophylaxis of Iron deficiency where inadequate diet calls for supplementary Zinc and Folic acid is justified during the remainder of pregnancy.
Special care should be taken in patients with Iron overload states, such as haemochromatosis, haemolytic anaemia or red blood cell aplasia. Failure to response to the treatment requires further investigations to exclude other causes of anaemia. In patients with renal failure there may be the risk of Zinc accumulation.